Sermorelin studies: growth, hormones and duration

Child growth: Thorner, 1996

The multicenter trial in prepubertal children with GH deficiency has an advantage over much of the adult discussion: it measured the outcome the treatment was intended to change. First-year height velocity rose from about 4.1 cm/year to roughly 7–8 cm/year, without excessive IGF-1 generation.

That is the sermorelin result I consider hardest to wave away. The population was children with growth hormone deficiency, and the endpoint was linear growth. The review of diagnostic and pediatric treatment use puts that work in its historical setting. An adult seeking better recovery comes to the same molecule with a different question.

Even the childhood record has texture. A longer pediatric study found GHRH antibodies in some responders without apparent interference with growth and reported no changes in glucose or lipid levels during therapy. I’m interested in that coexistence: an immune response and a continuing growth response, rather than an automatic equation between antibodies and failure.

Older men: Corpas, 1992

The short endocrine experiment in healthy older men enrolled 10 older men and used 9 young men as a comparison group. The older men’s mean age was 68 years. After 14 days, 24-hour GH and IGF-1 increased in a dose-related way; at the higher study amount, the measured parameters no longer differed from those of the young men. Fasting glucose did not change.

Restoring a laboratory measurement toward a younger group’s level is a real finding. Adding the word “rejuvenation” asks that blood result to carry a much larger conclusion. The paper did not establish whether the men felt better or obtained lasting functional gains.

The 24-hour measurement is worth lingering over. GH secretion arrives in pulses, so a whole day’s record asks a richer question than a single blood draw. It is still an endocrine endpoint. The dosage page retains the study’s actual amounts and route.

Continuous infusion: Tauber, 1993

Here the expected story becomes less tidy. In six children with partial GH deficiency followed during continuous infusion, an early rise in integrated GH gave way to a consistent decline by 3 to 6 months. One child showed complete suppression of GH secretion. The investigators considered several possible explanations, including GHRH antibodies, changes in somatostatin and desensitization of the pituitary receptors.

I’d give this experiment more space in the adult discussion. It challenges an easy assumption about duration while leaving its own explanation open. Continuous infusion differs from the intermittent administration in other studies, and the small group makes sweeping conclusions especially fragile. Calling this proof that every prolonged GHRH intervention fails would outrun the paper just as surely as ignoring it.

My initial preference for a longer-lasting signal became much less confident after this result. The useful follow-up would distinguish the pattern of stimulation from the amount of stimulation and measure meaningful outcomes over time. That is a question for further work, not a suggested regimen.

Sermorelin benefits and before-and-after claims

For sermorelin before and after, the documented changes here are height velocity in deficient children and hormone measurements in older men. The striking adult body-composition figures often quoted nearby came from the tesamorelin cognition trial: 152 older adults, including 66 with mild cognitive impairment, were studied for 20 weeks. IGF-1 rose 117%, percent body fat fell 7.4%, and cognition showed a favorable effect.

Tesamorelin is a stabilized GHRH analog. Those results make the family interesting; a sermorelin benefit claim still needs a sermorelin experiment. I object to silently changing the drug’s name when retelling an attractive result. The distinction matters for fat loss, muscle-building claims and claims about thinking alike.

The editorial cautioning against GH secretagogues for aging reaches a conclusion I share: the evidence has further to go before broad anti-aging use is justified. The unanswered experiment interests me more. An adult trial that followed function, symptoms and harms would do more to settle this argument than another appealing account of a blood marker.

Sermorelin side effects in clinical studies

Mild injection-site irritation appears in the comparative pediatric study. Nearly all participants developed GHRH antibodies, which did not correlate with growth; no serious side effects were reported in that study. An acute study in short children also recorded small, short-term rises in prolactin, luteinizing hormone and follicle-stimulating hormone.

Those findings make the pituitary look less like an isolated GH switch. The longer adult safety question remains open, including the theoretical concern about chronically raising growth-promoting hormones. The effects and safety page sets these observations beside the anecdotal reports and the findings from modified GHRH peptides.